0000000000661261

AUTHOR

Eleonora Turrini

0000-0003-4743-1126

showing 2 related works from this author

In Vitro Study of the Cytotoxic, Cytostatic, and Antigenotoxic Profile of Hemidesmus indicus (L.) R.Br. (Apocynaceae) Crude Drug Extract on T Lymphob…

2018

In traditional Indian medicine, the crude drug Hemidesmus indicus root—commonly known as Indian sarsaparilla—is used alone or in poly-herbal preparations for the treatment of a wide range of diseases. The present study focuses on the cancer chemopreventive and therapeutic potential of H. indicus extracts on an acute lymphoblastic leukemia cell line (CCRF-CEM). With this aim in mind, we subjected H. indicus roots to two subsequent extractions (hydro-alcoholic extraction and soxhlet extraction). As DNA damage is an important prerequisite for the induction of mutations/cancer by genotoxic carcinogens, cancer chemoprevention may be achieved by preventing genotoxicity. Through an integrated …

0301 basic medicineDNA damageCell SurvivalHealth Toxicology and MutagenesisPhytochemicalsHemidesmus indicus; cancer cells; apoptosis; cell cycle; genotoxicity; antigenotoxicityantigenotoxicitylcsh:MedicineCancer cellCrude drugPharmacologymedicine.disease_causeToxicologyProtective AgentsPlant RootsArticleNOHemidesmus indicus03 medical and health sciences0302 clinical medicineCell Line TumormedicineHumansCarcinogenHemidesmus indicusHemidesmusbiologyChemistryPlant Extractslcsh:RgenotoxicityapoptosisApoptosiHemidesmus indicuCell cyclePrecursor Cell Lymphoblastic Leukemia-Lymphomabiology.organism_classificationAntineoplastic Agents Phytogenic030104 developmental biologyApoptosis030220 oncology & carcinogenesisCancer cellcancer cellscell cycleGenotoxicity<i>Hemidesmus indicus</i>; cancer cells; apoptosis; cell cycle; genotoxicity; antigenotoxicityDNA DamageToxins
researchProduct

Balanced dual acting compounds targeting aromatase and estrogen receptor α as an emerging therapeutic opportunity to counteract estrogen responsive b…

2021

Abstract Breast Cancer (BC) is a leading cause of death in women, currently affecting 13% of female population worldwide. First-line clinical treatments against Estrogen Receptor positive (ER+) BC rely on suppressing estrogen production, by inhibiting the aromatase (AR) enzyme, or on blocking estrogen-dependent pro-oncogenic signaling, by targeting Estrogen Receptor (ER) α with selective Modulators/Degraders (SERMs/SERDs). The development of dual acting molecules targeting AR and ERα represents a tantalizing alternative strategy to fight ER + BC, reducing the incidence of adverse effects and resistance onset that limit the effectiveness of these gold-standard therapies. Here, in silico desi…

Molecular dynamicAntineoplastic Agents Hormonalmedicine.drug_classIn silicoEstrogen receptorBreast NeoplasmsMolecular dynamicsQM/MMBreast cancerbreast cancerDrug DiscoverymedicineHumansAromataseIC50Pharmacologychemistry.chemical_classificationbiologyAromatase InhibitorsMultitargetOrganic ChemistryEstrogen AntagonistsAromatase inhibitorGeneral Medicinemedicine.diseaseSERMEnzymechemistryEstrogenCell cultureSettore CHIM/03 - Chimica Generale E InorganicaSERDbiology.proteinCancer researchFemale
researchProduct